Not really a winning strategy selling a product for less than it costs to produce it. From the quarterly "Presently, the Company expects to shift towards anoperating cashflow neutral position in H2 CY2024" So the best that can be hoped for is "shifting towards" breaking even. wtf.
At best the company will be selling product at a loss for the rest of the year, the only ones benefiting from this company are staff and phosphate buyers. It is truly doomed. Might take another year of slow pain but ....
Not really a winning strategy selling a product for less than it...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
